Coherus and Junshi Biosciences Announce PD-1 Inhibitor Toripalimab Granted Orphan Drug Designation for Small Cell Lung Cancer in the United States
14 avr. 2022 08h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., and SHANGHAI, China, April 14, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”,...
Coherus and Junshi Biosciences Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
08 avr. 2022 13h10 HE
|
Coherus BioSciences, Inc.
SHANGHAI, China, and REDWOOD CITY, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Compass Therapeutics Presents Data on CTX-8371, a Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting
08 avr. 2022 13h01 HE
|
Compass Therapeutics
BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage oncology focused biotechnology company developing proprietary antibody-based therapeutics to...
Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event
29 mars 2022 09h15 HE
|
Coherus BioSciences, Inc.
— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth – — Introducing 2026 revenue target of $1.2...
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
15 mars 2022 08h00 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Rosh Dias, MD, MRCP, has been appointed Chief Medical...
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
15 mars 2022 07h30 HE
|
Coherus BioSciences, Inc.
– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary endpoint of overall survival compared to chemotherapy alone – - Data support the use...
Coherus and Junshi Biosciences Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell
04 mars 2022 08h00 HE
|
Coherus BioSciences, Inc.
- Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with advanced ESCC - - PFS and OS benefits were observed across all PD-L1 expression...
Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody
10 janv. 2022 07h30 HE
|
Coherus BioSciences, Inc.
• Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combinationin clinical trials in multiple tumor types • Combinations of PD-1 + TIGIT inhibitors have potential to expand...
Coherus and Junshi Biosciences Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
13 déc. 2021 07h00 HE
|
Coherus BioSciences, Inc.
SHANGHAI, China and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences,...
Coherus BioSciences Announces Upcoming Medical Conference Presentations
08 sept. 2021 08h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced upcoming medical conference presentations. Toripalimab clinical data...